Epidermal growth factor receptor inhibitor AG1478 inhibits mucus hypersecretion in airway epithelium

American Journal of Rhinology and Allergy

Volumn 30, Issue 1, 2016, Pages e1-e6

  Takezawa, Kumiko ^a   Ogawa, Takao ^a   Shimizu, Shino ^a   Shimizu, Takeshi ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; INTERLEUKIN 8; MESSENGER RNA; MUCIN 5AC; TUMOR NECROSIS FACTOR ALPHA; MUC5AC PROTEIN, RAT; QUINAZOLINE DERIVATIVE; TYRPHOSTIN;

ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG INHIBITION; GOBLET CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; METAPLASIA; MUCUS; MUCUS SECRETION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NOSE MUCOSA; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SECRETION; RAT; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INFLAMMATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FISCHER 344 RAT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; NEUTROPHIL; PHYSIOLOGY; PNEUMONIA; RESPIRATORY MUCOSA; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-8; MALE; MUCIN 5AC; MUCUS; NEUTROPHILS; PNEUMONIA; QUINAZOLINES; RATS; RATS, INBRED F344; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESPIRATORY MUCOSA; TYRPHOSTINS;

EID: 84959536270     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2016.30.4263     Document Type: Article

References (28)

1. Pawankar R, and Nonaka M. Inflammatory mechanisms and remodeling in chronic rhinosinusitis and nasal polyps. Curr Allergy Asthma Rep 7:202-208, 2007.
2. Al-Muhsen S, Johnson JR, and Hamid Q. Remodeling in asthma. J Allergy Clin Immunol 128:451-462; quiz 463-464, 2011.
3. Kouzaki H, Seno S, Fukui J, et al. Role of platelet-derived growth factor in airway remodeling in rhinosinusitis. Am J Rhinol Allergy 23:273-280, 2009.
4. Lee CG, Link H, Baluk P, et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med 10:1095-1103, 2004.
5. Shimizu S, Kouzaki H, Ogawa T, et al. Eosinophil-epithelial cell interactions stimulate the production of MUC5AC mucin and profibrotic cytokines involved in airway tissue remodeling. Am J Rhinol Allergy 28:103-109, 2014.
6. Shimizu S, Gabazza EC, Ogawa T, et al. Role of thrombin in chronic rhinosinusitis-associated tissue remodeling. Am J Rhinol Allergy 25:7-11, 2011.
7. Shimizu S, Ogawa T, Takezawa K, et al. Tissue factor and tissue factor pathway inhibitor in nasal mucosa and nasal secretion of chronic rhinosinusitis with nasal polyp. Am J Rhinol Allergy 29:235-242, 2015
8. Burgel PR, Escudier E, Coste A, et al. Relation of epidermal growth factor receptor expression to goblet cell hyperplasia in nasal polyps. J Allergy Clin Immunol 106:705-712, 2000.
9. Ding GQ, Zheng CQ, and Bagga SS. Up-regulation of the mucosal epidermal growth factor receptor gene in chronic rhinosinusitis and nasal polyposis. Arch Otolaryngol Head Neck Surg 133:1097-1103, 2007.
10. Shimizu S, Shimizu T, Morser J, et al. Role of the coagulation system in allergic inflammation in the upper airways. Clin Immunol 129:365-371, 2008.
11. Shimizu T, Takahashi Y, Kawaguchi S, and Sakakura Y. Hypertrophic and metaplastic changes of goblet cells in rat nasal epithelium induced by endotoxin. Am J Respir Crit Care Med 153:1412-1418, 1996.
12. Ogawa T, Shimizu S, Tojima I, et al. Heparin inhibits mucus hypersecretion in airway epithelial cells. Am J Rhinol Allergy 25:69-74, 2011.
13. Ono N, Kusunoki T, and Ikeda K. Relationships between IL-17A and macrophages or MUC5AC in eosinophilic chronic rhinosinusitis and proposed pathological significance. Allergy Rhinol (Providence) 3:e50-e54, 2012.
14. Rose MC, and Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 86:245-278, 2006.
15. Thornton DJ, and Sheehan JK. From mucins to mucus: Toward a more coherent understanding of this essential barrier. Proc Am Thorac Soc 1:54-61, 2004.
16. Otto BA, and Wenzel SE. The role of cytokines in chronic rhinosinusitis with nasal polyps. Curr Opin Otolaryngol Head Neck Surg 16:270-274, 2008.
17. Nakagome K, Matsushita S, and Nagata M. Neutrophilic inflammation in severe asthma. Int Arch Allergy Immunol 158:96-102, 2012.-1131, 2000.
18. Polosa R, Prosperini G, Leir SH, et al. Expression of c-erbB receptors and ligands in human bronchial mucosa. Am J Respir Cell Mol Biol 20:914-923, 1999.
19. McGovern T, Risse PA, Tsuchiya K, et al. LTD4 induces HB-EGFdependent CXCL8 release through EGFR activation in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 299:L808-L815, 2010.
20. Koff JL, Shao MX, Ueki IF, and Nadel JA. Multiple TLRs activate EGFR via a signaling cascade to produce innate immune responses in airway epithelium. Am J Physiol Lung Cell Mol Physiol 294:L1068-L1075, 2008.
21. Takeyama K, Dabbagh K, Jeong Shim J, et al. Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils. J Immunol 164:1546-1552, 2000.
22. Takeyama K, Tamaoki J, Kondo M, et al. Role of epidermal growth factor receptor in maintaining airway goblet cell hyperplasia in rats sensitized to allergen. Clin Exp Allergy 38:857-865, 2008.
23. Hur GY, Lee SY, Lee SH, et al. Potential use of an anticancer drug gefinitib, an EGFR inhibitor, on allergic airway inflammation. Exp Mol Med 39:367-375, 2007.
24. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292-4302, 2002.
25. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 361:137-139, 2003.
26. Pérez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with nonsmallcell lung cancer. J Clin Oncol 22:3238-3247, 2004.
27. Gemma A, Kudoh S, Ando M, et al. Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10, 708 Japanese patients with non-small-cell lung cancer. Cancer Sci 105:1584-1590, 2014.
28. Keating GM. Afatinib: A review of its use in the treatment of advanced non-small cell lung cancer. Drugs 74:207-221, 2014.